Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens. (academic.oup.com)

Authors: Castagna A … Prakash M Journal: Open Forum Infectious Diseases Published: 2026-09-01 DOI: https://doi.org/10.1093/ofid/ofag487